ROCKVILLE, Md. — Novavax has received a grant to support preclinical research of a vaccine for the most commonly identified cause of lower respiratory illnesses in infants and young children.
The respiratory syncytial virus also infects more than 8.5 million adults annually, causing severe pneumonia in older adults over age 65.
Novavax’s vaccine candidate has been shown to protect mice against RSV disease and can be produced at sufficient yields and high purity to allow commercial manufacture.
The $246,000 grant from the National Institute of Allergy and Infectious Diseases will support research using calves, which are susceptible to RSV and have illnesses similar to those seen in infants with RSV.